This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/projekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F68378050%3A_____%2F02%3A23033173%21RIV%2F2004%2FAV0%2FA23004%2FN/
n18http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F68378050%3A_____%2F02%3A23033173%21RIV%2F2004%2FAV0%2FA23004%2FN
rdf:type
n11:Vysledek skos:Concept
dcterms:description
Oncogenic, moderately immunogenic, MHC class I- and class II-, B7(-), MK16/l/III ABC (MK16) cells were previously established by co-transfection of HPV16 E6/E7 and activated H-ras oncogene DNA into C57BL/6 kidney cells. Subcutaneous transplantation of these cells produced progressively growing local neoplasms which metastasized spontaneously to lungs and lymph nodes. The MK16 cells were implanted into syngeneic mice and used to examine whether the tumour lacking the signal molecules required for the induction of and sensitivity to T cell immunity is susceptible to local IL-2 treatment and IL-2 gene therapy. Peritumoural administration of human rIL-2 or murine IL-2 gene-modified MK16 tumour vaccine inhibited growth of subcutaneous MK16 tumour transplants and reduced the number of their lung metastases. These results indicate that experimental tumours which are MHC class I- and mimick in this respect a high proportion of human HPV16-associated carcinomas are suitable for IL-2 treatment. Oncogenic, moderately immunogenic, MHC class I- and class II-, B7(-), MK16/l/III ABC (MK16) cells were previously established by co-transfection of HPV16 E6/E7 and activated H-ras oncogene DNA into C57BL/6 kidney cells. Subcutaneous transplantation of these cells produced progressively growing local neoplasms which metastasized spontaneously to lungs and lymph nodes. The MK16 cells were implanted into syngeneic mice and used to examine whether the tumour lacking the signal molecules required for the induction of and sensitivity to T cell immunity is susceptible to local IL-2 treatment and IL-2 gene therapy. Peritumoural administration of human rIL-2 or murine IL-2 gene-modified MK16 tumour vaccine inhibited growth of subcutaneous MK16 tumour transplants and reduced the number of their lung metastases. These results indicate that experimental tumours which are MHC class I- and mimick in this respect a high proportion of human HPV16-associated carcinomas are suitable for IL-2 treatment.
dcterms:title
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
skos:prefLabel
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
skos:notation
RIV/68378050:_____/02:23033173!RIV/2004/AV0/A23004/N
n4:strany
643;646
n4:aktivita
n15:P n15:Z
n4:aktivity
P(NC5900), Z(AV0Z5052915)
n4:cisloPeriodika
20
n4:dodaniDat
n8:2004
n4:domaciTvurceVysledku
n10:6215319 n10:1572830 n10:1723758 n10:4531140 n10:3714977 n10:9414185 n10:8003726
n4:druhVysledku
n16:J
n4:duvernostUdaju
n17:S
n4:entitaPredkladatele
n13:predkladatel
n4:idSjednocenehoVysledku
667496
n4:idVysledku
RIV/68378050:_____/02:23033173
n4:jazykVysledku
n9:eng
n4:klicovaSlova
HPV16, IL-2; tumour vaccines; gene therapy
n4:klicoveSlovo
n14:gene%20therapy n14:HPV16 n14:IL-2 n14:tumour%20vaccines
n4:kodStatuVydavatele
GR - Řecká republika
n4:kontrolniKodProRIV
[121382A4A506]
n4:nazevZdroje
International Journal of oncology
n4:obor
n5:EB
n4:pocetDomacichTvurcuVysledku
7
n4:pocetTvurcuVysledku
10
n4:pocetUcastnikuAkce
0
n4:pocetZahranicnichUcastnikuAkce
0
n4:projekt
n7:NC5900
n4:rokUplatneniVysledku
n8:2002
n4:svazekPeriodika
2002
n4:tvurceVysledku
Indrová, Marie Šímová, Jana Žák, R. Mikyšková, Romana Mendoza, Luis Vonka, V. Jandlová, Táňa Bubeník, Jan Bieblová, Jana Šmahel, M.
n4:zamer
n18:AV0Z5052915
s:issn
1019-6439
s:numberOfPages
4